公开(公告)号：US20200253996A1

公开(公告)日：2020-08-13

申请号：US16651719

申请日：2018-10-01

申请人： UNIVERSITE PARIS-SUD ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  INSTITUT GUSTAVE-ROUSSY

发明人： Samir MESSAOUDI ,  Mouad ALAMI ,  Jean-Daniel BRION ,  Amélie CHABRIER ,  Adam TELERMAN ,  Robert AMSON

IPC分类号： A61K31/706 ,  A61K31/7068 ,  A61P35/00 ,  A61K31/015 ,  A61K31/085 ,  A61K31/03 ,  A61K31/09 ,  A61K31/235 ,  A61K31/11 ,  A61K31/165 ,  A61K31/352 ,  A61K31/404 ,  A61K31/472 ,  A61K31/382 ,  A61K31/704 ,  A61K31/197 ,  A61K31/24 ,  A61K31/135

摘要： The present invention relates to the compounds of formula (I) below: wherein: X represents an oxygen atom, a sulfur atom, a nitrogen atom or a CH radical, The bond X—Y and Y are absent if X represents an oxygen or sulfur atom, the bond X—Y and Y are present if X represents a nitrogen atom or a CH radical, When present, Y represents a group R if X represents a nitrogen atom, a hydrogen atom or a group —NR1R2 if X represents a CH radical, (Het)Ar is an aromatic ring selected from the group consisting of aryl and heteroaryl groups, R3, R4, R5, R6 represent, independently of one another, a hydrogen atom, a halogen atom, a —NR12R13, a —SR14 group, a —OR14 group or a —CF3 group, When Y is —NR1R2, the groups —NR1R2 and (Het)Ar are in the cis-conformation, or a pharmaceutically acceptable salt thereof, for use in the treatment of proliferative diseases, infectious diseases, allergies, inflammation and/or asthma.

公开(公告)号：US20180105574A1

公开(公告)日：2018-04-19

申请号：US15559984

申请日：2016-03-21

申请人： Universite Paris Descartes ,  Assistance Publique - Hopitaux de Paris ,  Universite Paris - SUD ,  Unviversite Pierre et Marie Curie (Paris 6) ,  Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Centre National de la Recherche Scientifique (CNRS) ,  Institut Gustave-Roussy

发明人： Nicolas Dupin ,  Philippe Grange ,  Vincent Calvez ,  Joël Raingeaud

IPC分类号： C07K14/75 ,  A61P29/00 ,  A61P17/10 ,  A61P17/06 ,  C12N7/00 ,  A61K9/00

CPC分类号： C07K14/75 ,  A61K9/0014 ,  A61K9/0019 ,  A61K38/00 ,  A61P17/06 ,  A61P17/10 ,  A61P29/00 ,  C07K2319/00 ,  C12N7/00

摘要： A present invention relates to isolated peptides obtained from human fibrinogen for their use as drug, particularly for the prevention and/or the treatment of inflammatory skin diseases, more particularly acne. The present invention also relates to fragments of these polypeptides, nucleic acid molecules encoding them, expression vectors, host cells, a pharmaceutical composition and a combination product containing them, and their use for treating and/or preventing inflammatory skin diseases, particularly acne.

公开(公告)号：US09938528B2

公开(公告)日：2018-04-10

申请号：US15534321

申请日：2015-12-10

申请人： INSERM (Institut National de la Sante et de la Recherche Medicale) ,  Universite Paris-Sud ,  Institut Gustave Roussy ,  Universite Paris Descartes ,  Universite Pierre et Marie Curie (Paris 6) ,  Institut Pasteur ,  Istituto Nazionale per Le Malattie Infettive IRCCS Lazzaro Spallanzani ,  Assistance Publique-Hopitaux de Paris (APHP)

发明人： Guido Kroemer ,  Jean-Luc Perfettini ,  Marie-Lise Gougeon ,  Awatef Allouch ,  Mauro Piacentini

IPC分类号： C12N15/11 ,  C12N15/113 ,  A61K45/06 ,  A61K31/683 ,  A61K31/5517 ,  A61K31/165 ,  A61K31/395 ,  A61K31/17 ,  A61K31/713 ,  C12Q1/18

CPC分类号： C12N15/113 ,  A61K31/165 ,  A61K31/17 ,  A61K31/395 ,  A61K31/5517 ,  A61K31/683 ,  A61K31/7088 ,  A61K31/713 ,  A61K45/06 ,  C12N15/1132 ,  C12N2310/14 ,  C12N2320/31 ,  C12Q1/18 ,  A61K2300/00

摘要： The present invention provides methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections. In particular, the present invention relates to a method for treating HIV-1 infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an inhibitor of SGT1 activity or expression.

公开(公告)号：US09862931B2

公开(公告)日：2018-01-09

申请号：US13643788

申请日：2011-04-28

申请人： Karim Benihoud ,  Anastasia Lanzi ,  Michel Perricaudet

发明人： Karim Benihoud ,  Anastasia Lanzi ,  Michel Perricaudet

IPC分类号： C12N7/00 ,  C07K14/005 ,  A61K39/235 ,  A61K39/00 ,  C12N15/86

CPC分类号： C12N7/00 ,  A61K39/00 ,  A61K2039/5256 ,  A61K2039/545 ,  A61K2039/55 ,  C07K14/005 ,  C12N15/86 ,  C12N2710/10322 ,  C12N2710/10343 ,  C12N2710/10362

摘要： The invention relates to recombinant adenovirus displaying one or more heterologous epitope(s) on their fiber protein. These recombinant adenovirus are useful as vaccines for generating an immune response against said epitope(s) in individuals having a pre-existing anti-Ad immunity.

公开(公告)号：US09682137B2

公开(公告)日：2017-06-20

申请号：US14363095

申请日：2012-12-07

申请人： VIROXIS S.A.S. ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE PARIS-SUD XI ,  INSTITUT GUSTAVE ROUSSY

发明人： Thierry Heidmann

IPC分类号： A61K39/12 ,  A61K39/21 ,  C07K14/005

CPC分类号： A61K39/21 ,  A61K39/12 ,  C07K14/005 ,  C12N2740/15022 ,  C12N2740/15034 ,  C12N2740/16122 ,  C12N2740/16134

摘要： A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.

公开(公告)号：US09297046B2

公开(公告)日：2016-03-29

申请号：US13426040

申请日：2012-03-21

申请人： Franck Viguie ,  Olivier Bernard ,  Michaela Fontenay ,  Christian Bastard ,  Francois Delhommeau ,  William Vainchenker

发明人： Franck Viguie ,  Olivier Bernard ,  Michaela Fontenay ,  Christian Bastard ,  Francois Delhommeau ,  William Vainchenker

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156

摘要： The present invention concerns an in vitro method for diagnosing a myeloid tumor or a lymphoid tumor in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO:2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumor or a lymphoid tumor.

摘要翻译： 本发明涉及一种用于诊断受试者中骨髓瘤或淋巴样肿瘤的体外方法，其包括通过以下步骤：分析来自所述受试者的生物样品：（i）检测十一易位蛋白家族中的突变的存在 编码具有序列SEQ ID NO：2的多肽的成员2基因（TET2）和/或（ii）分析TET2基因的表达; 其中检测这种TET2突变，不存在TET2的表达或截短的TET2的表达指示受试者发展或倾向于发展骨髓瘤或淋巴样肿瘤。

公开(公告)号：US09194003B2

公开(公告)日：2015-11-24

申请号：US13515984

申请日：2010-12-21

申请人： Robert Ballotti ,  Corine Bertolotto ,  Brigitte Bressac De Paillerets ,  Mahaut De Lichy ,  Fabienne Lesueur

发明人： Robert Ballotti ,  Corine Bertolotto ,  Brigitte Bressac De Paillerets ,  Mahaut De Lichy ,  Fabienne Lesueur

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156

摘要： The present invention relates to a mutant of MITF which is useful as a marker for predisposition to the development of cancer and to uses thereof in diagnosis and preventive treatments, sumoylation being reduced or absent in this mutant.

摘要翻译： 本发明涉及MITF的突变体，其可用作癌症发展倾向的标志物及其在诊断和预防性治疗中的用途，该突变体中sumoylation被减少或不存在。

公开(公告)号：US20150232932A1

公开(公告)日：2015-08-20

申请号：US14428649

申请日：2013-09-17

申请人： INSTITUT GUSTAVE ROUSSY

发明人： Dominique Bluteau ,  Remi Favier ,  Hana Raslova ,  William Vainchenker

IPC分类号： C12Q1/68 ,  G01N33/68

CPC分类号： C12Q1/6883 ,  C12Q2600/158 ,  G01N33/57426 ,  G01N33/6893 ,  G01N2333/4703 ,  G01N2333/4712 ,  G01N2800/222 ,  G01N2800/226

摘要： An in vitro method for diagnosing thrombocytopenia in a subject, the method includes the step of assessing the ANKRD26 platelet expression in a biological sample from the subject, wherein a ANKRD26 platelet expression is indicative of a thrombocytopenia. Also described is a kit for diagnosing a thrombocytopenia in a subject, which includes at least one ANKRD26 nucleic acid probe or oligonucleotide or antibody for assessing the ANKRD26 platelet expression in a biological sample from the subject.

摘要翻译： 用于诊断受试者血小板减少症的体外方法，所述方法包括评估来自受试者的生物样品中ANKRD26血小板表达的步骤，其中ANKRD26血小板表达指示血小板减少症。 还描述了用于诊断受试者血小板减少症的试剂盒，其包括用于评估来自受试者的生物样品中的ANKRD26血小板表达的至少一种ANKRD26核酸探针或寡核苷酸或抗体。

公开(公告)号：US20150185202A1

公开(公告)日：2015-07-02

申请号：US14412571

申请日：2013-07-08

申请人： INSTITUT GUSTAVE-ROUSSY

发明人： Jean-Luc Perfettini ,  Guido Kroemer ,  Eric Deutsch

IPC分类号： G01N33/50 ,  C12N15/113

CPC分类号： G01N33/5011 ,  C12N15/113 ,  C12N15/1135 ,  C12N2310/14 ,  C12N2310/141 ,  C12Q1/6881 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156 ,  G01N33/566 ,  G01N33/574 ,  G01N33/57496 ,  G01N33/6872 ,  G01N2800/52

摘要： The present inventors show that cannibal cells can undergo senescence after entosis in vivo and that the tumor suppressive protein p53 act as a repressor of this phenomenon. They therefore propose new tools to study the molecular pathways involved in the cannibalism process, for example by measuring the expression levels of p53 or splice variants thereof (such as Δ133TP53, TP53β, TP53γ or Δ40TP53), the release of extracellular ATP or purinergic P2Y2 receptor activity. The present inventors also demonstrated that the detection of senescent cannibal cells in breast adenocarcinoma obtained from patients treated with neo-adjuvant therapy positively correlates with good patient's response to treatment. Altogether, these results provide the first evidence that detection of cellular cannibalism and senescence simultaneously in tumors helps for the diagnosis of disease outcomes and for the prediction of treatment efficiency against cancer diseases.

摘要翻译： 本发明人表明，食人族细胞在体内诱导后可以衰老，并且肿瘤抑制蛋白p53作为该现象的阻遏物。 因此，他们提出了新的工具来研究自相残疾过程中涉及的分子途径，例如通过测量p53或其剪接变体（例如＆Dgr; 133TP53，TP53＆bgr;TP53γ或＆Dgr; 40TP53）的表达水平，细胞外释放 ATP或嘌呤能P2Y2受体活性。 本发明人还证实，从用新辅助治疗的患者获得的乳腺腺癌中衰老食饵细胞的检测与良好的患者对治疗的反应正相关。 总之，这些结果提供了第一个证据，即在肿瘤中同时检测细胞嗜食性和衰老有助于诊断疾病结果，并预测治疗效果对抗癌症疾病。

公开(公告)号：US20150030623A1

公开(公告)日：2015-01-29

申请号：US14507455

申请日：2014-10-06

申请人： Merial Limited ,  Centre National De la Recherche Scientifique ,  Institut Gustave Roussy ,  Universite Paris-Sud

发明人： Herve Poulet ,  Thierry Heidmann

IPC分类号： C07K14/005 ,  C12N7/00 ,  C12N15/86

CPC分类号： C07K14/005 ,  A61K31/04 ,  A61K38/162 ,  A61K39/12 ,  A61K39/21 ,  A61K39/275 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/70 ,  A61K2300/00 ,  C07K14/15 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/24043 ,  C12N2710/24044 ,  C12N2740/13022 ,  C12N2740/13034 ,  C12N2800/22

摘要： The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.